SpecialtiesQuestion

How do you decide between HERIZON-GEA01 and KEYNOTE-811 trials when determining treatment approach for metastatic gastric/GE adenocarcinoma?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you do adjuvant chemo in patient pT3N0 colon with intussusception on imaging and partial obstruction on colonoscopy?

Do you incorporate the ALASCCA trial into your clinical practice and perform NGS on all early stage colon cancer patients to determine if adjuvant aspirin would be beneficial?

Are you using tarlatamab for neuroendocrine carcinomas (NECs) and poorly differentiated neuroendocrine tumors of GI (non-lung) origins?

How are you interpreting the early RASolute 302 trial findings (daraxonrasib) in metastatic PDAC?

How do you manage toxicities in patients with mPDAC receiving daraxonrasib?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.